
    
      OUTLINE:

      Patients receive carboplatin intravenously (IV) over 30 minutes on day -2 of cycle 1 only.
      Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat
      every 6 weeks for up to 2 years in the absence of disease progression or unacceptable
      toxicity.

      After the completion of study treatment, patients are followed up at 30 days, then every 3
      months for year 1, and every 6 months for year 2.
    
  